Clinical trials sponsored by Alnylam Pharmaceuticals

Phase breakdown

Conditions studied

Recruiting trials led by Alnylam Pharmaceuticals

• A Study to Evaluate ALN-4324 on Insulin Sensitivity in Adults With Type 2 Diabetes Mellitus
  NCT07465224 · Phase: Phase 2 · Ages: 18 Years to 65 Years · Sex: All (male and female) · 1 location
• A Study to Evaluate ALN-5288 in Patients With Alzheimer's Disease
  NCT07214727 · Phase: Phase 1 · Ages: 40 Years to 80 Years · Sex: All (male and female) · 13 locations
• A Study to Evaluate ALN-6222 in Participants With Obesity
  NCT07624071 · Phase: Phase 1 · Ages: 18 Years to 65 Years · Sex: All (male and female) · 1 location
• A Study to Evaluate ALN-AGT01 RVR in Adult Patients With Mild to Moderate Hypertension Pretreated With Zilebesiran
  NCT07553442 · Phase: Phase 2 · Ages: 18 Years to 75 Years · Sex: All (male and female) · 3 locations
• A Study to Evaluate Mivelsiran in Adult Participants With Early-Stage Down Syndrome-Associated Alzheimer's Disease (DS-AD)
  NCT07636811 · Phase: Phase 2 · Ages: 40 Years to 55 Years · Sex: All (male and female) · 3 locations
• A Study to Evaluate the Safety and Tolerability of ALN-APP in Patients With EOAD
  NCT05231785 · Phase: Phase 1 · Ages: 18 Years and older · Sex: All (male and female) · 8 locations
• Zilebesiran in Patients With Hypertension Not Adequately Controlled and With Either Established Cardiovascular Disease or High Risk for Cardiovascular Disease
  NCT07181109 · Phase: Phase 3 · Ages: 18 Years and older · Sex: All (male and female) · 1105 locations

Common questions

How many trials is Alnylam Pharmaceuticals recruiting for?

Alnylam Pharmaceuticals is the lead sponsor of 7 recruiting trials.

Is this list complete?

No. For the full record, search ClinicalTrials.gov.